Intralipid Versus SMOFlipid in HPN Patients
Short Bowel SyndromeIntestinal Fistula2 moreThis study will randomize all patients who are new to the Mayo Clinic HPN team to either standard lipid emulsion (Intralipid) or SMOFLipid.
Registry for Participants With Short Bowel Syndrome
Short Bowel SyndromeThis is a global prospective, observational, multi-center registry to evaluate the long-term safety profile for participants with short bowel syndrome (SBS) who are treated with teduglutide in a routine clinical setting. The registry will also evaluate the long-term clinical outcomes in participants with SBS. SBS participants treated and not treated with teduglutide will be enrolled.
Loperamide vs. Placebo's Effect on Ileostomy Output: A Clinical Randomized Blinded Cross-over Study...
Rectal CancerUlcerative Colitis1 moreClinical experience show limited effect of the drug Loperamide used to decrease output in stoma patients. Therefore the investigators see the need for a randomized blinded clinical trial to determine the effect of Loperamide opposite Placebo. Loperamide will be evaluated in relation to the following parameters Change in ileostomy output in g/day in relation to oral intake Quantification of the change in intestinal transit time using a radiopaque marker The patient´s own assessment on which period they received Loperamide or Placebo
The Use of DPP-4 Inhibitors in Short Bowel Syndrome
Short Bowel SyndromeThe inhibition of Dipeptidyl peptidase-4 should increase the concentration of glucagone-like peptide 1 and 2, and the increase of the latter should increase the absorptive capacity of the intestine.
Safety and Dosing Study of Glucagon-like Peptide 2 (GLP-2) in Infants and Children With Intestinal...
Intestinal FailureShort Bowel SyndromeThis protocol outlines a randomized,open label trial examining the safety, pharmacology and efficacy of Glucagon like peptide 2 (GLP-2) in infants and children with intestinal failure. The investigators hypothesize that GLP-2 given subcutaneously in these patients will be well tolerated, and have similar metabolism to what has been shown in adults. The investigators also expect to show an improvement in the tolerance of enteral nutrition, and a decreased requirement for intravenous feeding.
Safety and Efficacy Study in Infant With SBS
Short Bowel SyndromeThe objective of this clinical study is to evaluate the efficacy and safety of NTRA-9620 compared with placebo in pediatric subjects (aged 28 weeks postmenstrual age to 52 weeks old) with SBS following surgical resection
Evaluate the Efficacy and Safety Growth Hormone, Glutamine and Diet in Patients With Short Bowel...
Short Bowel SyndromeTreatment for 3.5-8 weeks with GH (0.05 mg/kg/day) +GLN+Diet, followed by continued compliance to the individualized oral diet and enteral GLN, will result in reduced volume of TPN infusion/week and/or reduced frequency of TPN infusions/week.
Pediatric Teduglutide Registry
Short Bowel SyndromePediatric specific post-marketing registry to evaluate the long-term safety and efficacy of teduglutide.
VIBRANT Study of Vurolenatide in Adult Patients With Short Bowel Syndrome.
Short Bowel SyndromeA Study of Vurolenatide in Adult Patients with Short Bowel Syndrome.
Efficacy And Safety Evaluation of Glepaglutide in Treatment of Short Bowel Syndrome (SBS)
Short Bowel SyndromeThe primary objective of the trial is to confirm the efficacy of glepaglutide in reducing parenteral support volume in patients with short bowel syndrome. Glepaglutide is the International Nonproprietary Name and USAN for ZP1848.